Report cover image

Cell & Gene Therapy Manufacturing: Scalability & Market Access Strategy

Publisher ResearchCubes
Published Mar 31, 2026
Length 72 Pages
SKU # RCUB21142025

Description

Strategic analysis of CGT manufacturing bottlenecks limiting commercialization. Covers regulatory pathway maturation, HTA reimbursement uncertainty, and manufacturing scale-up economics. Market projections ($5.88B to $80B+) with capability assessment.

Table of Contents

72 Pages
EXECUTIVE SUMMARY
1.1 CGT Market Overview & Growth Projections
1.2 Manufacturing Readiness Assessment
2.0 MANUFACTURING CHALLENGES
2.1 Autologous Therapy Manufacturing Economics
2.2 Allogeneic Approach & Scale-Up
2.3 Distributed Manufacturing Requirements
3.0 REGULATORY & REIMBURSEMENT
3.1 ATMP Regulatory Pathway Evolution
3.2 HTA & Pricing Strategy
3.3 Durability Data Requirements
4.0 VALUE CHAIN INTEGRATION
4.1 CDMO Partnership Strategy
4.2 Vertical Integration vs. Outsourcing
4.3 Time-to-Revenue Risk Management
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.